Study: NCT04787991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab (Cohort A)
Description: Nivolumab will be administered intravenously at 360 mg every 3 weeks for up to 2 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab (Cohort A, B and C)
Description: For Cohort A and B, ipilimumab will be administered intravenously at 1mg/kg every 6 weeks for up to 2 cycles. For Cohort C, ipilimumab will be administered intravenously at 1mg/kg on C2D1 and C4D1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab (Cohort A, B and C)
Description: For Cohort A and B, ipilimumab will be administered intravenously at 1mg/kg every 6 weeks for up to 2 cycles. For Cohort C, ipilimumab will be administered intravenously at 1mg/kg on C2D1 and C4D1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab (Cohort A, B and C)
Description: For Cohort A and B, ipilimumab will be administered intravenously at 1mg/kg every 6 weeks for up to 2 cycles. For Cohort C, ipilimumab will be administered intravenously at 1mg/kg on C2D1 and C4D1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) (Cohort B)
Description: Hydroxychloroquine will be administered orally daily for up to 2 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel (nP) (Cohort A, B and C)
Description: Nab-paclitaxel will be administered intravenously at 125 mg/m2 for 2 weeks on and 1 week off, for at least 24 weeks, unless treatment discontinuation criteria are met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel (nP) (Cohort A, B and C)
Description: Nab-paclitaxel will be administered intravenously at 125 mg/m2 for 2 weeks on and 1 week off, for at least 24 weeks, unless treatment discontinuation criteria are met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel (nP) (Cohort A, B and C)
Description: Nab-paclitaxel will be administered intravenously at 125 mg/m2 for 2 weeks on and 1 week off, for at least 24 weeks, unless treatment discontinuation criteria are met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine (gem) (Cohort A, B and C)
Description: Gemcitabine will be administered intravenously at 1000 mg/m2 for 2 weeks on and 1 week off, for at least 24 weeks, unless treatment discontinuation criteria are met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine (gem) (Cohort A, B and C)
Description: Gemcitabine will be administered intravenously at 1000 mg/m2 for 2 weeks on and 1 week off, for at least 24 weeks, unless treatment discontinuation criteria are met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine (gem) (Cohort A, B and C)
Description: Gemcitabine will be administered intravenously at 1000 mg/m2 for 2 weeks on and 1 week off, for at least 24 weeks, unless treatment discontinuation criteria are met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NG350A (Cohort C)
Description: NG-350A will be administered intravenously on Cycle 1 Days 15 (1e12 viral particles), 17 (3e12 viral particles), and 19 (3e12 viral particles).